Current management of hepatobiliary malignancies between centers with or without a liver transplant program: A multi-society national survey
Matteo Serenari,Roberta Angelico,Quirino Lai,Damiano Patrono,Irene Scalera,Emanuele Kauffmann,Duilio Pagano,Riccardo De Carlis,Enrico Gringeri,Alessandro Vitale,AICEP-SITO-CCTF study group,Adelmo Antonucci,Alberto Brolese,Alberto Patriti,Aldo Rocca,Alessandro Ferrero,Alessandro Iacomino,Amedeo Carraro,Andrea Ruzzenente,Antonio Frena,Antonio Giuliani,Bruno Nardo,Christian Cotsoglou,Edoardo Saladino,Elio Jovine,Enzo Andorno,Ettore Colangelo,Fabrizio Di Benedetto,Fabrizio Romano,Fausto Zamboni,Felice Giuliante,Francesco Izzo,Francesco Tandoi,Fulvio Calise,Giacomo Zanus,Gian Luca Baiocchi,Gian Luca Grazi,Giorgio Ercolani,Giovanni Vennarecci,Giuseppe Maria Ettorre,Giuseppe Tisone,Guido Griseri,Guido Torzilli,Leonardo Vincenti,Lorenzo Livraghi,Luca Aldrighetti,Luca Morelli,Luca Vigano,Luciano De Carlis,Lucio Caccamo,Lucio Urbani,Luigi Boccia,Luigi Veneroni,Marcello Giuseppe Spampinato,Marcello Maestri,Marco Massani,Marco Spada,Marco Vivarelli,Massimo Fedi,Massimo Rossi,Matteo Barabino,Matteo Cescon,Matteo Donadon,Matteo Ravaioli,Michele Achille Crespi,Michele Ciocca Vasino,Michele Colledan,Michele Mazzola,Mohammed Abu Hilal,Nazario Portolani,Nicola Cinardi,Paola Tarchi,Paolo De Simone,Raffaele Dalla Valle,Renato Romagnoli,Riccardo Memeo,Roberto Lauro,Roberto Santambrogio,Roberto Troisi,Salvatore Gruttadauria,Salvatore Agnes,Silvio Guerriero,Stefano Berti,Ugo Boggi,Umberto Baccarani,Umberto Cillo,Vincenzo Mazzaferro
DOI: https://doi.org/10.1016/j.dld.2024.09.007
2024-10-07
Abstract:Background: Availability of liver transplantation (LT) as a treatment for hepatocellular carcinoma (HCC) and other liver malignancies may determine heterogeneity of therapeutic strategies across different centers. Aims: To investigate the practice between hepato-biliary centers without (HB centers) and with a LT program (LT centers), we launched a 38-item web-based national survey, with directors of centers as a target. Methods: The survey, including 4 clinical vignettes, collected data on their approach to HCC and transplant oncology. Results: After duplicates removal, 75 respondents were considered. Respondents from LT centers (n = 22, 29.3 %) were more in favor of LT in the case of HCC outside Milan criteria (90.9 % vs. 67.9 %, p = 0.037), recurrent HCC (95.5 % vs. 50.9 %, p = 0.002) and other malignancies such as cholangiocarcinoma or neuroendocrine tumors. No significant difference was observed concerning the proportion of centers favorable to LT for unresectable colorectal liver metastases (100 % vs. 88.7 %, p = 0.100). Conclusion: This national survey showed how management of HCC and awareness of transplant oncology may differ between HB and LT centers. Effective networking between HB and LT centers is crucial to provide optimal treatment and access to LT.